【热门产品推荐】派安普利单抗，Penpulimab， AntibodySystem Laboratories

派安普利单抗，Penpulimab，CAS: 2350298-92-7，AntibodySystem Laboratories

货号：DHH02225

产品链接：http://www.atagenix.com/product_detail-74831.html

别名：AK-105, CAS: 2350298-92-7

简介：

派安普利单抗 Penpulimab 是一种 IgG1 抗 PD-1 单克隆抗体，具有抗肿瘤活性。

货号：DHH02225

产品品牌：Antibodysystem

通用名：Penpulimab

纯度：>95% by SDS-PAGE.

浓度：1mg/ml

Formulationicon：0.01M PBS, pH 7.4.

内毒素：Please contact with the lab for this information.

别名：AK-105

靶点;物种：Human CD279/PDCD1/PD1

种类：Humanized

受体鉴定：IgG1-Kappa

CAS: 2350298-92-7

存储条件：

Use a manual defrost freezer and avoid repeated freeze-thaw cycles.

Store at +4°C short term (1-2 weeks).

Store at -20 °C 12 months.

Store at -80°C long term.

参考文献：

Penpulimab: First Approval. PMID: 34813051

Antibodies to watch in 2022. PMID: 35030985

Penpulimab, an anti-PD1 IgG1 antibody in the treatment of advanced or metastatic upper gastrointestinal cancers. PMID: 35165764

Penpulimab, an Fc-Engineered IgG1 Anti-PD-1 Antibody, With Improved Efficacy and Low Incidence of Immune-Related Adverse Events. PMID: 35833116

Clinical Activity and Safety of Penpulimab (Anti-PD-1) With Anlotinib as First-Line Therapy for Unresectable Hepatocellular Carcinoma: An Open-Label, Multicenter, Phase Ib/II Trial (AK105-203). PMID: 34327136

Penpulimab for Relapsed or Refractory Classical Hodgkin Lymphoma: A Multicenter, Single-Arm, Pivotal Phase I/II Trial (AK105-201). PMID: 35875118

Corrigendum: Successful treatment of a patient with multiple-line relapsed extensive-stage small-cell lung cancer receiving penpulimab combined with anlotinib: A case report. PMID: 36033531

Autoimmune hemolytic anemia in patients with relapsed Hodgkin's lymphoma after treatment with penpulimab, a monoclonal antibody against programmed death receptor-1. PMID: 35503192

Successful Treatment of a Patient With Multiple-Line Relapsed Extensive-Stage Small-Cell Lung Cancer Receiving Penpulimab Combined With Anlotinib: A Case Report. PMID: 35321433